KraneShares CSI China Internet ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? KraneShares CSI China Internet ETF trades at $24.96 (market cap $4.37B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 5.7× KraneShares CSI China Internet ETF's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| KWEB | ROIV | |
|---|---|---|
Market Cap | $4.37B | $24.72B |
Volume | 13,393,361 | 6,279,442 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $41.81 |
52-Week Low | $23.63 | $16.04 |
Typical Hold Time | 57 Days | 1 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.87, up 2.22% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell, while oscillators are neutral. Recent news highlights institutional activity, including a stake reduction by Tidal Investments LLC and an increase by HSBC Holdings PLC, amid ongoing U.S.-China trade dynamics and economic data releases.
The outlook for KWEB is clouded by geopolitical tensions and economic headwinds in China, though corporate profit growth offers a potential catalyst. Key risks include trade policy shifts and weak domestic consumption. Investors should weigh institutional movements against broader market sentiment for balanced exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →